Home / Publications / Annual Review 2019 – 2020 / Managing risk / ST Pharm establishes new medical testing and analysis...
  1. Facing the future
    1. Selling the Merkur offshore wind farm
    2. The green economy: identifying primary risks and key opportunities
    3. ALPLA expands its global plastic recycling capabilities
    4. Solving global challenges
    5. Advising on a EUR 1.1bn Bulgarian gas pipeline procurement
    6. Ukrainian Gas Transmission System unbundling
  2. Navigating a changing world
    1. Data and risk: challenges in an uncertain world
    2. CMS advises on major East Africa paint transaction
    3. Commerz Real lands the largest deal in its history
    4. Helping Teyliom Hospitality’s expansion in Central and West Africa
    5. Shaping the new normal
    6. Working through the COVID-19 lockdown
  3. Harnessing technology
    1. Technology: a unifying force
    2. Online gambling grows as Gamesys is sold to JPJ Group
    3. CMS advises on first ever European real estate transaction using blockchain
    4. CymbiQ Group on expansion course
    5. CMS helps Korean investors acquire prime real estate assets
    6. Lupl delivers transformative open industry platform for legal matters
    7. MultiChoice separates from Naspers and lists on JSE
    8. CMS advises on ‘Train Maya’ rail project
    9. Smart living: creating a framework for disruption and innovation
    10. CMS helps the BBC launch the streaming service BritBox in the UK
  4. Managing risk
    1. The true cost of ESG
    2. CMS advises Blackstone on its investment in Carrix
    3. CMS advises Zentiva on its acquisition of Alvogen
    4. ST Pharm establishes new medical testing and analysis business line
    5. Colgate-Palmolive acquires premium anti-ageing skin care brand
  5. Inside CMS
    1. CMS Academy adds participants through digital learning
  6. CSR and Diversity & Inclusion
    1. Médecins Sans Frontières (MSF): CMS Charity Partner
    2. Diversity and Inclusion at CMS UK
  7. Partner interviews
    1. Interview with Gabriela Staber
    2. Interview with Sophie Marquet
    3. Interview with Courtney Rothery
    4. Interview with María González Gordon
    5. Interview with Mariel Dimsey
    6. Interview with Nedžida Salihović-Whalen
    7. Interview with Annemieke Hazelhoff
    8. Interview with Michelle Barclay
    9. Interview with Deepa Vallabh
    10. Interview with Gerlind Wisskirchen

ST Pharm establishes new medical testing and analysis business line

CMS was able to seamlessly coordinate a cohesive and extremely responsive team.
Toby Grainger

 

ST Pharm Co. Ltd, a major Korean pharmaceuticals manufacturer, acquired a 70% stake in Swiss contract laboratory services and histopathology company AnaPath Services in November 2019. At the same time, AnaPath purchased a 100% share in Envigo CRS, a Spanish contract research organisation. The businesses will integrate under the AnaPath Research brand.

The synergies and strategic value of the acquisitions are extremely significant. The world-class research business capabilities of the Spanish operations, paired with the advanced laboratory and testing competences from AnaPath Services, enable ST Pharm to rapidly accelerate its new drug development and contract development and manufacturing (CDMO) ambitions. This is something that would have taken considerably longer through a domestic and organic approach.

Led by Singapore-based partner Toby Grainger, CMS teams in Singapore, Spain and Switzerland advised the acquirers on both transactions.

The deals posed a number of legal challenges. The CMS team in Spain, for example, had to navigate the local entity out of a statutory winding down process, directly negotiate with unionised employee representatives and coordinate an effective resolution to debt and capitalisation deficiencies. CMS was able to swiftly mobilise its employment expertise to ensure participation in meetings and negotiations was smooth and seamless. Beyond local issues, there was the negotiation of a technical services agreement, handled by the Singapore team. The negotiation was made more complex as the vendor counterparty had itself been recently sold to another US group and was hence reliant on its new parent delivering on the transitional services to a large extent (in particular, ensuring support for the completion of ongoing clinical trials).

According to Toby Grainger, “CMS was able to seamlessly coordinate a cohesive and extremely responsive team working across different countries and time zones to ensure the transaction flowed and completed in an efficient manner. The team’s familiarity with the relevant issues, turnaround on documentation and working ‘as one’, meant that expertise could be mobilised swiftly and effective resolutions presented to the client in a time-sensitive backdrop.”

Key contacts

Toby Grainger
Toby Grainger
Managing Partner
Head of Corporate and Indonesian Desk, Singapore